Real‐time detection of hepatic micrometastases from pancreatic cancer by intraoperative fluorescence imaging
Open Access
- 11 October 2011
- Vol. 118 (11) , 2813-2819
Abstract
BACKGROUND: Recently, a highly sensitive fluorescent imaging technique was developed for the real‐time identification of hepatic tumors. The authors applied this procedure for the intraoperative detection of radiographically occult hepatic micrometastases from pancreatic cancer.METHODS: Forty‐nine consecutive patients with pancreatic cancer who underwent surgical intervention were examined. Preoperative clinical images had not revealed any hepatic metastases. On the day before surgery, indocyanine green was injected intravenously. During the operation, the liver was observed with a near‐infrared camera system, and abnormal fluorescent foci were examined by frozen‐section histology. The patients with hepatic micrometastases were judged to have unresectable disease and underwent only palliative surgery followed by systemic chemotherapy using gemcitabine.RESULTS: Abnormal hepatic fluorescence at least 1.5 mm in greatest dimension without any apparent tumor was observed in 13 patients. Among them, histologic examination confirmed micrometastases in 8 of 49 patients (16%). All patients with hepatic micrometastases had clinical T3 or T4 disease and high serum CA19‐9 levels (P = .042). On follow‐up computed tomography images that were obtained within 6 months after surgery, the patients with hepatic micrometastases manifested hepatic overt metastases (7 of 8 patients; 88%) more frequently than the patients without hepatic micrometastases (4 of 41 patients; 10%; P < .001). Regardless of histologic confirmation, the positive predictive value of abnormal fluorescence for the manifestation of hepatic relapse within 6 months was 77% (10 of 13 patients), and the negative predictive value was 97% (35 of 36 patients).CONCLUSIONS: Indocyanine green‐fluorescent imaging can detect hepatic micrometastases of pancreatic cancer during surgery. The hepatic micrometastases seem to have an adverse clinical impact identical to that of evident distant metastases. Cancer 2011. © 2011 American Cancer Society.Keywords
This publication has 30 references indexed in Scilit:
- Surgical Implication of Micrometastasis for Pancreatic CancerPancreas, 2010
- Liver-Directed Therapy for Hepatic Metastases in Patients Undergoing PancreaticoduodenectomyAnnals of Surgery, 2010
- Liver Perfusion Chemotherapy With 5-Fluorouracil Followed by Systemic Gemcitabine Administration for Resected Pancreatic CancerPancreas, 2009
- Preoperative CA 19-9 and the Yield of Staging Laparoscopy in Patients with Radiographically Resectable Pancreatic AdenocarcinomaAnnals of Surgical Oncology, 2008
- Usefulness of intraoperative fluorescence imaging to evaluate local anatomy in hepatobiliary surgeryJournal of Hepato-Biliary-Pancreatic Surgery, 2008
- Randomized Phase III Trial of Adjuvant Chemotherapy with Gemcitabine versus S-1 in Patients with Resected Pancreatic Cancer: Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01)Japanese Journal of Clinical Oncology, 2008
- Prophylactic hepatic irradiation following curative resection of pancreatic cancerJournal of Hepato-Biliary-Pancreatic Surgery, 2005
- Near-infrared fluorescent type II quantum dots for sentinel lymph node mappingNature Biotechnology, 2003
- Detection of Hepatic Micrometastasis in Pancreatic Adenocarcinoma Patients by Two‐stage Polymerase Chain Reaction/Restriction Fragment Length Polymorphism AnalysisJapanese Journal of Cancer Research, 1995
- Patterns of failure after curative resection of pancreatic carcinomaCancer, 1990